Neratinib FDA approval date

The FDA approved Neratinib (Nerlynx) on 17 Jul 2017.

FDA approval date
17 Jul 2017

Drug identity checked against registry records

Also recorded as Nerlynx

Included trials

TrialSponsorPhaseStatusPrimary completion
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926PBYIPhase 2Terminated2023-01-02Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2017-07-17DayNeratinibFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA208051", "applicant_as_listed_by_fda": "PUMA BIOTECH", "brand_names": ["NERLYNX"], "active_ingredients": ["NERATINIB MALEATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170717", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026